Search Results for: SRC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel LRP1 LDL receptor related protein 1
  • Scavenging of heme from plasma
  • Retinoid metabolism and transport
  • Antihemophilic factor, human recombinant
  • Tenecteplase
  • Coagulation Factor IX (Recombinant)
  • Lanoteplase
  • Von Willebrand factor human
  • Coagulation Factor IX Human
  • Lonoctocog alfa
  • Moroctocog alfa
Novel MAP2 microtubule associated protein 2
  • Estramustine
  • Paclitaxel
  • Docetaxel
Novel MAP2K1 mitogen-activated protein kinase kinase 1
  • MAPK3 (ERK1) activation
  • Frs2-mediated activation
  • Signal transduction by L1
  • Uptake and function of anthrax toxins
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • K-252a
  • 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
  • Cobimetinib
  • Bosutinib
  • (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
  • 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
  • Mirdametinib
  • N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
  • 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
  • Trametinib
  • Selumetinib
  • Pimasertib
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel MAPK15 mitogen-activated protein kinase 15
  • Acetylsalicylic acid
  • Minocycline
  • Colforsin
  • Fostamatinib
Novel MAPK3 mitogen-activated protein kinase 3
  • MAPK3 (ERK1) activation
  • RAF-independent MAPK1/3 activation
  • ISG15 antiviral mechanism
  • Signaling by NODAL
  • Spry regulation of FGF signaling
  • Signaling by Activin
  • Frs2-mediated activation
  • ERK/MAPK targets
  • ERK/MAPK targets
  • ERKs are inactivated
  • Regulation of actin dynamics for phagocytic cup formation
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Oncogene Induced Senescence
  • FCERI mediated MAPK activation
  • Regulation of HSF1-mediated heat shock response
  • NCAM signaling for neurite out-growth
  • RSK activation
  • Signal transduction by L1
  • Activation of the AP-1 family of transcription factors
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate NADPH Oxidases
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RNA Polymerase I Promoter Opening
  • Signal attenuation
  • Interferon gamma signaling
  • Advanced glycosylation endproduct receptor signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • ESR-mediated signaling
  • RUNX2 regulates osteoblast differentiation
  • Regulation of PTEN gene transcription
  • Regulation of the apoptosome activity
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Suppression of apoptosis
  • Signaling downstream of RAS mutants
  • Signaling by MAP2K mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • Nuclear events stimulated by ALK signaling in cancer
  • IFNG signaling activates MAPKs
  • Negative Regulation of CDH1 Gene Transcription
  • NPAS4 regulates expression of target genes
  • NPAS4 regulates expression of target genes
  • Growth hormone receptor signaling
  • Signaling by LTK in cancer
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Sulindac
  • Acetylsalicylic acid
  • Minocycline
  • Arsenic trioxide
  • Colforsin
  • Purvalanol
  • 5-iodotubercidin
  • Seliciclib
  • Cholecystokinin
  • Ulixertinib
Novel MAPK8IP3 mitogen-activated protein kinase 8 interacting protein 3
Novel MAPRE1 microtubule associated protein RP/EB family member 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • EML4 and NUDC in mitotic spindle formation
Novel MAPT microtubule associated protein tau
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Flortaucipir F-18
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
Novel MATK megakaryocyte-associated tyrosine kinase
  • Downregulation of ERBB2 signaling
  • Fostamatinib
Novel MDM2 MDM2 proto-oncogene
  • AKT phosphorylates targets in the cytosol
  • Oxidative Stress Induced Senescence
  • Oncogene Induced Senescence
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • Trafficking of AMPA receptors
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ub-specific processing proteases
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Stabilization of p53
  • Regulation of RUNX3 expression and activity
  • Signaling by ALK fusions and activated point mutants
  • Degradation of CDH1
  • NPAS4 regulates expression of target genes
  • Zinc
  • Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
  • Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Penile cancer
  • Alveolar rhabdomyosarcoma
  • Choriocarcinoma
  • Osteosarcoma
  • Glioma
Novel MED28 mediator complex subunit 28
  • PPARA activates gene expression
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • RSV-host interactions
Novel MET MET proto-oncogene, receptor tyrosine kinase
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D mediated inhibition of cell attachment and migration
  • RAF/MAP kinase cascade
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • MECP2 regulates neuronal receptors and channels
  • Drug-mediated inhibition of MET activation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Sunitinib
  • K-252a
  • SGX-523
  • 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
  • N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
  • 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
  • N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
  • 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
  • AMG-208
  • 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
  • Crizotinib
  • Cabozantinib
  • Capmatinib
  • Tivozanib
  • Fostamatinib
  • Tivantinib
  • Brigatinib
  • Amuvatinib
  • Tepotinib
  • Amivantamab
  • Cholangiocarcinoma
  • Gastric cancer
  • Renal cell carcinoma
Novel MICAL1 microtubule associated monooxygenase, calponin and LIM domain containing 1
  • Factors involved in megakaryocyte development and platelet production
Novel MPZL1 myelin protein zero like 1
Novel MST1R macrophage stimulating 1 receptor
  • Signaling by MST1
  • Crizotinib
  • Fostamatinib
Novel MT-ND2 NADH dehydrogenase subunit 2
  • Mitochondrial translation termination
  • Respiratory electron transport
  • Complex I biogenesis
  • Mitochondrial protein degradation
  • NADH
  • Leber optic atrophy; Leber hereditary optic atrophy (LHON)
Novel MUC1 mucin 1, cell surface associated
  • Defective GALNT3 causes HFTC
  • Defective C1GALT1C1 causes TNPS
  • Defective GALNT12 causes CRCS1
  • Dectin-2 family
  • Interleukin-4 and Interleukin-13 signaling
  • O-linked glycosylation of mucins
  • Termination of O-glycan biosynthesis
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Alveolar Cells
  • TG4010
Novel MYLK myosin light chain kinase
  • Smooth Muscle Contraction
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • Ritodrine
  • Fostamatinib
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
Novel NANS N-acetylneuraminate synthase
  • Sialic acid metabolism
Novel NCOA6 nuclear receptor coactivator 6
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional regulation of white adipocyte differentiation
  • Regulation of lipid metabolism by PPARalpha
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Cytoprotection by HMOX1
  • Heme signaling
  • Formation of WDR5-containing histone-modifying complexes
  • Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression

Page 9 out of 32 pages